Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Design Therapeutics Inc (NQ: DSGN )

5.570 +0.090 (+1.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Design Therapeutics Inc

< Previous 1 2 3 4 Next >
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
From Design Therapeutics, Inc.
Via GlobeNewswire
Earnings Preview For Design Therapeutics
Via Benzinga
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them. 
Via InvestorPlace
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024
DSGN stock results show that Design Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
From Design Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023
DSGN stock results show that Design Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 19, 2024
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million. 
Via Benzinga
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
From Design Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
Over $5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
Topics Stocks
Exposures US Equities
Market Sentiment Teeters As US Indices, Including S&P 500, Break Key Supports: Next Levels To Watch
All three leading U.S. stock indices — the S&P 500, Nasdaq 100, and Russell 2000 — have simultaneously breached a crucial technical support level this week. 
Via Benzinga
Topics Stocks
Exposures US Equities
Design Therapeutics' Modified DT-216 May Have Potential, But Analyst Awaits Further Developments
RBC Capital Market downgraded Design Therapeutics Inc (NASDAQ: DSGN) from Outperform to Sector Perform with a price target of $7,  
Via Benzinga
Nasdaq Falls 100 Points; Siyata Mobile Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 100 points on Tuesday. The Dow traded down 0.82% to 35,017.95 while the NASDAQ fell 0.77% to 13,682.54. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Shares of Design Therapeutics Are Plummeting on Tuesday
The biotech company released phase 1 trial details regarding a Friedreich ataxia therapy. 
Via The Motley Fool
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Crude Oil Down 2%; Home Depot Posts Upbeat Earnings
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 90 points on Tuesday. The Dow traded down 0.75% to 35,042.16 while the NASDAQ fell 0.66% to 13,697.15. The S&P... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023
Via Benzinga
Dow Falls Over 200 Points; US Retail Sales Top Expectations
U.S. stocks traded lower this morning, with the Dow Jones falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.67% to 35,069.60 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Design Therapeutics Stock Moving Lower Today?
Design Therapeutics Inc (NASDAQ: DSGN) reported initial results from the company's Phase 1 multiple-ascending dose (MAD) clinical trial of DT-216 in  
Via Benzinga
Why Delcath Systems Shares Are Trading Higher By Around 58%; Here Are 20 Stocks Moving Premarket
Gainers Delcath Systems, Inc. (NASDAQ: DCTH) shares surged 57.7% to $4.93 in pre-market trading after the company reported the FDA approval of HEPZATO KIT™ for the treatment of adult patients with... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.